Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TBI 1301

Drug Profile

TBI 1301

Alternative Names: NY-ESO-1 antigen-specific RetroNectin® TCR gene therapy - Takara Bio; NY-ESO-1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara Bio; NY-ESO-1 siTCR gene therapy; NY-ESO-1-antigen-specific-T-cell-receptor-gene-therapy; NY-ESO-1-specific-t-cells; NY-ESO-1-T-cells; NY-ESO-1-TCR; NY-ESO-1-TCR-gene-therapy-Takara; NY-ESO-1-TCR-PBMC; NY-ESO-1-TCR-transduced-lymphocytes; NY-ESO-1-transduced-t-cells; NY-ESO-1-transduced-t-lymphocytes; TBI-1301; TBI-1301A

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takara Bio
  • Developer Fred Hutchinson Cancer Research Center; Mie University; National Cancer Institute (USA); Takara Bio; University Health Network
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Soft tissue sarcoma; Synovial sarcoma
  • Phase I T-cell lymphoma
  • No development reported Sarcoma; Solid tumours

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Recurrent) in Canada (IV, Infusion)
  • 31 May 2019 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 31 May 2019 Updated efficacy data from a phase I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top